Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,546 result(s) found for: Solid Tumor. Displaying page 6 of 78.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2013-003009-24 Sponsor Protocol Number: F17752GE101QO Start Date*: 2013-09-30
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: PHASE I-II STUDY OF F17752 IN PATIENTS WITH ADVANCED SOLID TUMOURS
    Medical condition: patients with advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002732-24 Sponsor Protocol Number: FP2CLI001 Start Date*: 2018-11-29
    Sponsor Name:Faron Pharmaceuticals Ltd
    Full Title: A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in ...
    Medical condition: Selected solid tumours; - cutaneous melanoma - pancreatic ductal adenocarcinoma - ovarian cancer - colorectal adenocarcinoma - hepatocellular carcinoma - gallbladder cancer and cholangiocarcinoma...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001842-82 Sponsor Protocol Number: W00101-IV-1-01 Start Date*: 2017-11-15
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, mu...
    Medical condition: Advanced or metastatic solid tumors (excluding lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020962 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005751-21 Sponsor Protocol Number: BLU-285-1408 Start Date*: 2021-04-16
    Sponsor Name:Blueprint Medicines
    Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study
    Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012769-74 Sponsor Protocol Number: A4021040 Start Date*: 2009-09-02
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 110017
    Full Title: PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-001175-31 Sponsor Protocol Number: ALM201/0001 Start Date*: 2014-10-10
    Sponsor Name:Almac Discovery
    Full Title: A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.
    Medical condition: Advanced ovarian cancer and other solid tumours
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002017-22 Sponsor Protocol Number: 63723283LUC1001 Start Date*: 2016-11-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with A...
    Medical condition: Advanced Stage Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001402-20 Sponsor Protocol Number: D910FC00001 Start Date*: 2019-11-27
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
    Medical condition: Various types of cancer ( dependent on parent study)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) HU (Completed) PL (Completed) ES (Ongoing) GR (Completed) BE (Completed) BG (Completed) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003604-75 Sponsor Protocol Number: CHDM201X2103C Start Date*: 2015-05-11
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma
    Medical condition: Liposarcoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003118-42 Sponsor Protocol Number: D419EC00001 Start Date*: 2019-04-16
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patien...
    Medical condition: Advanced Solid Tumors and Hematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003497-14 Sponsor Protocol Number: BLU-285-1303 Start Date*: 2018-04-23
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003407-38 Sponsor Protocol Number: 8669-062 Start Date*: 2012-01-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Paediatric Patients with Advanced Solid Tumours
    Medical condition: Advanced solid tumours including lymphoma and tumours of the central nervous system.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005604-35 Sponsor Protocol Number: APEC1621B Start Date*: 2022-01-18
    Sponsor Name:National Cancer Institute (NCI)
    Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
    Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-002241-22 Sponsor Protocol Number: CA186-107 Start Date*: 2014-12-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodg...
    Medical condition: Advanced Solid Tumors Advanced B-cell NHL
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10065252 Solid tumor LLT
    17.1 100000004864 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001662-85 Sponsor Protocol Number: 3144A1-2206-WW Start Date*: 2008-11-24
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Phase 1/2 Randomized, Open-label, Three Arm Study of Neratinib (HKI-272) vs. Neratinib + Capecitabine vs. Lapatinib + Capecitabine, in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or l...
    Medical condition: Solid tumors (part 1) and metastatic breast cancer (part 2)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004548-12 Sponsor Protocol Number: RPL-001-16 Start Date*: 2017-08-30
    Sponsor Name:Replimune Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors [IGNYTE]
    Medical condition: Advanced solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000579-18 Sponsor Protocol Number: IMMU-132-11 Start Date*: 2022-06-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
    Medical condition: Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001725-40 Sponsor Protocol Number: CV202-103 Start Date*: 2017-10-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors.
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004011-37 Sponsor Protocol Number: 673-203 Start Date*: 2015-07-20
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 2, Multicenter, Open-Label, Exploratory Biomarker Study of Talazoparib (BMN 673) Monotherapy in Patients with Recurrent or Metastatic Solid Tumors
    Medical condition: Recurrent or Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000999-42 Sponsor Protocol Number: CTMX-M-072-002 Start Date*: 2019-11-21
    Sponsor Name:CytomX Therapeutics, Inc
    Full Title: A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072-002)
    Medical condition: Treatment of solid tumors, including advanced/unresectable or metastatic cancer and neoadjuvant/resectable
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 03:49:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA